Soluble in DMSO (up to 25 mg/ml).
MS-275 (209783-80-2) is a potent HDAC inhibitor. Selective for HDAC1 (IC50 = 300 nM) over HDAC3 (IC50 = 8 μM) and HDAC8 (IC50 100 μM). In vivo, MS-275, has been shown to inhibit tumor growth via induction of the tumor supressors p21WAF1/CIP1 and gelsolin and to block cell proliferation in a variety of cancer cell lines. MS-275 has also shown significant anti-rheumatic activity in rat and mouse arthritis models.
Research or further manufacturing use only, not for food or drug use.